Can CBD Help with Epilepsy? Here Is What the Research Actually Says

When most people think about CBD, they think about stress relief or better sleep. But for some families, CBD represents something much more significant: a potential lifeline for children and adults living with severe, treatment-resistant epilepsy. This is one of the most researched areas in cannabidiol science, and the findings are genuinely compelling, though they come with important nuances worth understanding.

Let us walk through what the science actually says, clearly and honestly.

The FDA Said Yes: That Is a Big Deal

In 2018, the FDA approved Epidiolex, a pharmaceutical-grade purified form of cannabidiol, as a prescription medication. It is currently approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients one year and older. These are rare but devastating conditions that often do not respond well to conventional medications.

To earn FDA approval, a drug must pass rigorous clinical trials demonstrating both safety and efficacy. The fact that a CBD-based medication cleared that bar is significant. It means that for specific patients, pharmaceutical CBD is not just a wellness trend, it is a legitimate, evidence-backed treatment option.

What The Lancet Neurology Found

Some of the most cited early research came from a 2016 open-label trial published in The Lancet Neurology, led by neurologist Orrin Devinsky and colleagues. The study followed 162 children and young adults with severe, treatment-resistant epilepsy who were added CBD as part of their existing treatment. The results showed a meaningful reduction in monthly motor seizures for many participants, and the treatment was generally tolerated, though side effects including drowsiness, decreased appetite, and diarrhea were reported.

A 2019 review by Friedman, French, and Maccarrone, also published in The Lancet Neurology, broadened the picture further, discussing the cumulative evidence for cannabinoids across multiple neurological conditions. Together, these publications helped build the scientific foundation that supported regulatory review of pharmaceutical CBD.

Where Research Stands Today

As of 2025, research continues through systematic reviews, real-world data from expanded access programs, and ongoing clinical studies. Scientists are examining not just whether CBD reduces seizure frequency, but how it interacts with other medications, how to optimize dosing, and which patient profiles respond best.

One recurring theme in the literature is the importance of medical supervision. CBD can interact with certain antiepileptic drugs, particularly clobazam, and can affect liver enzyme levels. These are not reasons to avoid it, but they are reasons why this type of treatment belongs under a doctor's care, not self-managed.

An Honest Note About Over-the-Counter CBD

We want to be straightforward with you. The CBD studied in clinical trials and approved by the FDA is a pharmaceutical-grade product manufactured under strict standards. Over-the-counter hemp-derived CBD products, including ours, are not the same as Epidiolex and have not been evaluated for epilepsy treatment.

We share this research because we believe you deserve accurate information. Knowing the difference between what has been clinically proven and what is still being explored matters, especially for families navigating serious medical conditions. If you or someone you love has epilepsy, please work with a qualified neurologist. That conversation is the most important one to have.

The Bottom Line

The science behind CBD and epilepsy is one of the more mature areas of cannabinoid research, and it is genuinely encouraging. A pharmaceutical form of CBD has earned FDA approval, peer-reviewed studies in leading journals have documented real reductions in seizure frequency for certain patients, and research is still actively growing. That is worth knowing and worth talking about openly.

At Tonify, we are committed to sharing the science honestly, without overpromising what CBD can do. If you have questions about our third-party tested products for general wellness purposes, we are happy to help. And if this topic raised questions for you personally, please bring them to your doctor first.

Research Sources

1. Devinsky, O. et al. "Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial." The Lancet Neurology, 15(3), 270-278 (2016). DOI: 10.1016/S1474-4422(15)00379-8

2. Friedman, D., French, J.A., Maccarrone, M. "Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders." The Lancet Neurology, 18(5), 504-512 (2019). DOI: 10.1016/S1474-4422(19)30032-8

3. U.S. Food and Drug Administration. "FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana." FDA.gov (2018).

Disclaimer: This article summarizes publicly available research and is not intended as medical advice. Tonify products are dietary supplements and are not FDA-approved to treat any disease, including epilepsy. Always consult your physician before use, especially if you have a medical condition or take medications.